NCT01480713View on ClinicalTrials.gov

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
HIV-1 Infection
Interventions
DRUG

Isentress® (Raltegravir, 400 mg every 12 hours)

Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours

DRUG

Isentress® (Raltegravir, 400 every 12 hours)

Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours

Trial Locations (1)

08916

Germans Trias i Pujol Hospital, Badalona

All Listed Sponsors
lead

IrsiCaixa

OTHER

NCT01480713 - Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors | Biotech Hunter | Biotech Hunter